Data shown is for informational purposes only and does not constitute investment advice. TopFund is not SEBI-registered. Consult a SEBI-registered advisor before investing.

IM

Integris Medtech IPO

Upcoming MAINBOARD BSE, NSE · Medical Equipment & Supplies
60/100 TopFund Score

Price Band

₹

Issue Size

—

Lot Size

—

Min Investment

—

GMP

Grey Market Premium — the unofficial premium buyers are currently willing to pay over the issue price once this IPO lists. It's an informal market estimate, not guaranteed, and can move daily right up to listing day. Learn more: GMP vs Kostak vs Sauda →

—

Issue Price

—

Integris Medtech IPO AI Summary

  • Integris Medtech IPO is upcoming on BSE, NSE in the Medical Equipment & Supplies sector.
  • Subscription window: 27 Nov–01 Dec 2026, listing on 04 Dec 2026.

Integris Medtech Ltd is preparing for an IPO with a focus on expanding its medical device and laboratory solutions business. Despite recent profitability improvements, potential investors should weigh the company's market position against the inherent risks of investing in IPOs.

TopFund is not SEBI-registered — this is educational analysis, not personalized investment advice.

Important Dates

IPO Open Date
Fri, 27 Nov 2026 in 7d
IPO Close Date
Tue, 01 Dec 2026 in 11d
Allotment Date
Wed, 02 Dec 2026 in 12d
Refund Initiation
Thu, 03 Dec 2026 in 13d
Credit of Shares
Thu, 03 Dec 2026 in 13d
Listing Date
Fri, 04 Dec 2026 in 14d

Subscription Status

IPO not open yet

Opens 27 Nov 2026 · in 7 days

Integris Medtech IPO Grey Market Premium (GMP) Today

GMP not available yet

Grey Market Premium is updated daily. Check back closer to the listing date.

TopFund Score — Listing Data Indicator

Composite Score

60/100

As of 20 Nov 2026 · How we calculate this →

Moderate Signal
GMP Strength (35%) N/A

GMP not yet available

Subscription Demand (30%) N/A

Subscription not open yet

Anchor Investor Interest (15%) N/A

No anchor allocation for this IPO

Historical Similar-IPO Performance (20%) 60/100

Similar IPOs (same IPO type) averaged 17.8% listing gain

A rules-based composite of GMP, subscription demand, anchor participation and comparable-IPO history — each weighted as shown above. Not a statistically validated probability, a guarantee of listing performance, or personalized investment advice.

Limitations: weights are fixed by TopFund, not backtested against outcomes; the "Historical Similar-IPO Performance" factor needs at least 3 comparable past listings and falls back to a broader, less specific cohort when this sector/type doesn't have enough; GMP and subscription data can change daily right up to listing day, so scores shown may already be stale — check the "as of" date above.

About the Company

Incorporated in 2008, Integris Medtech Ltd is a diversified India-based global medical products and laboratory solutions company. The company develops, manufactures, commercialises, and sells a broad portfolio of medical devices and solutions spanning cardiovascular devices, clinical diagnostics, and scientific laboratory solutions. Integris Medtech operates manufacturing facilities in India, Germany, and the Netherlands, supplying products to more than 65 international markets across India, Europe, and Southeast Asia. Its customer base includes over 9,500 laboratories and 2,000 hospitals and cathlabs, supported by a portfolio exceeding 22,000 SKUs across more than 200 brands in laboratory and cardiovascular segments. The company’s business is structured into two core divisions: Cardiovascular Devices – encompassing drug-eluting stents, drug-coated balloons, complex coronary intervention products, and vascular access solutions. Laboratory Solutions – covering clinical, research, and industrial laboratory equipment, reagents, and consumables, along with services such as instrument installation, maintenance, and calibration through its BioCal™ brand. Integris Medtech supports laboratories and hospitals across India, Singapore, Thailand, Malaysia, and the Philippines, serving both public and private sectors. Its European operations focus primarily on cardiovascular products, including proprietary brands like Chrome and Protégé, while its Rest of World presence spans the Middle East, Africa, and Latin America. As of June 30, 2025, Integris Medtech employed 1,879 personnel, including sales, service, and application specialists, and had supported more than 15,000 patients across 100+ clinical trial sites globally, reinforcing its commitment to clinical evidence and innovation in MedTech solutions.

Company Financials (₹ Cr)

As of 2025-06-30

Period Ended 30 Jun 2025 31 Mar 2025 31 Mar 2024 31 Mar 2023
Assets 4,019.62 3,641.34 2,989.20 2,553.87
Total Income 508.93 1,959.58 1,582.26 1,369.66
Profit After Tax 267.57 70.68 -4.88 -40.54
EBITDA 78.73 309.40 190.45 168.82
NET Worth 3,889.99 2,752.52 2,681.02 2,629.52
Reserves and Surplus 2,299.84 1,150.74 1,135.71 1,073.12
Total Borrowing 793.42 1,729.46 813.10 556.54

Key Ratios

EPS

₹6.52

NAV

₹316.09

ROE

5.35%

ROCE

14.51%

RoNW

1.48%

PAT Margin

3.72%

Peer Comparison

Company NAV RoNW P/E (x) EPS Basic EPS Diluted
Laxmi Dental 37.71 16.09% 53.95 6.07 6.05
Poly Medicure 278.46 12.26% 56.02 34.13 34.11
Our Company This IPO 316.09 1.84% — 5.82 5.73

Promoters

Evercure Holdings Pte.Ltd., Medicore Holdings Pte.Ltd., Gurmit Singh Chugh and Punita Sharma

Objects of the Issue

# | Issue Objects | Est Amt (₹ Cr.) 1 | Repayment/ prepayment, in full or in part, of certain outstanding borrowings, interest accrued and prepayment penalties, as applicable, availed by: | 509.85 2 | The wholly-owned Subsidiaries, namely, Translumina Therapeutics Pvt.Ltd. (Translumina Therapeutics), Transhealth Pvt.Ltd. (Transhealth) ) and HaleMed Medical Pvt.Ltd. | 93.87 3 | The step-down Subsidiaries, namely, CPC Diagnostics Pvt.Ltd., Chemopharm Sdn. Bhd., Chemoscience Pte Ltd., Lifeline Diagnostics Supplies Inc., Hausen Bernstein Co. Ltd, Medigene Sdn. Bhd., Research Instruments Sdn Bhd and Research Instruments Pte. Ltd. | 415.98 4 | General Corporate Purposes | | Total | 1,019.70

Pros & Cons

Strengths

  • Diverse product portfolio in medical devices
  • Strong international market presence
  • Positive recent profit trend

Risks

  • Recent negative profit figures
  • Dependence on international markets
  • High competition in medical equipment sector

IPO Evaluation

Generated 20 Nov 2026

Revenue Trend

Total income was ₹1,369.66 Cr in the year ending 31 Mar 2023, increasing to ₹1,582.26 Cr by 31 Mar 2024. This growth continued, reaching ₹1,959.58 Cr by 31 Mar 2025, though the most recent figure of ₹508.93 Cr for the period ending 30 Jun 2025 is not directly comparable as it reflects only part of the fiscal year.

Profit Trend

Profit after tax was negative at ₹-40.54 Cr for the year ending 31 Mar 2023, improving to ₹-4.88 Cr by 31 Mar 2024. By 31 Mar 2025, profit turned positive at ₹70.68 Cr, and further increased to ₹267.57 Cr in the period ending 30 Jun 2025, though this is a 9-month figure, not a full year, so isn't directly comparable.

Valuation

The implied P/E ratio at the issue price is not calculable with the provided data.

Grey Market Premium, Explained

The grey market refers to unofficial trading of shares before they are listed on the stock exchange. Grey market premium (GMP) indicates the expected listing price compared to the issue price. A higher GMP suggests strong demand, while a lower GMP may indicate weaker interest.

Who This IPO Suits

Investors comfortable with short-term volatility and a long-term horizon typically weigh IPOs like this against their risk appetite and market conditions.

Who May Want to Wait

Conservative investors or those averse to market fluctuations may consider avoiding this IPO.

Listing Gains — The Risk

Listing day gains can be unpredictable. Factors influencing the stock price include market conditions, investor sentiment, and overall demand for the IPO. It's essential to consider these risks before investing.

This evaluation is generated from Integris Medtech's own public IPO filing data for educational purposes and is not investment advice or a recommendation to apply, subscribe to, or avoid this issue — see Broker Recommendations below for named third-party research views (clearly attributed, not TopFund's own). TopFund is not a SEBI-registered investment adviser — see our Disclaimer.

Frequently Asked Questions

When does Integris Medtech IPO open and close?

Integris Medtech IPO opens on 27 November 2026 and closes on 01 December 2026.

When does Integris Medtech IPO list on the stock exchange?

Integris Medtech IPO is scheduled to list on 04 December 2026.

What is the TopFund Listing Data Indicator for Integris Medtech?

Integris Medtech's Listing Data Indicator score is 60/100 (Moderate signal), a weighted composite of GMP strength, subscription demand, anchor investor interest and how similar past IPOs performed on listing. It's a rules-based summary of public market data, not a statistically validated probability, a guarantee, or personalized investment advice.

What is the lot size for this IPO?

The lot size information is not available.

What is the minimum investment required?

The minimum investment details are not provided.

What is the price band for the IPO?

The price band has not been disclosed.

When does the IPO open and close?

The IPO opens on 27 Nov 2026 and closes on 01 Dec 2026.

What does GMP mean?

GMP indicates the expected premium of the stock in the grey market before listing.

Issue Details

Issue Type MAINBOARD Book Built
Issue Size —
Price Band ₹ (Fixed)
Issue Price —
Lot Size —
Min Investment —
Exchange BSE, NSE
Sector Medical Equipment & Supplies
Open Date 27 Nov 2026
Close Date 01 Dec 2026
Allotment 02 Dec 2026
Listing Date 04 Dec 2026

Investor Allocation

QIB (Institutional) 50%
NII / HNI 15%
Retail (RII) 35%

Registrar

Kfin Technologies Ltd.

Lead Managers / Book Running

ICICI Securities Ltd.
Citigroup Global Markets India Pvt.Ltd.
IIFL Capital Services Ltd.
Axial Capital Pvt.Ltd.

IPO Timeline

Open

27 Nov 2026

Close

01 Dec 2026

Allotment

02 Dec 2026

Listing

04 Dec 2026

Community Sentiment

What are other investors planning for Integris Medtech?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

No comments yet — start the discussion.